Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer

Jan Harder, Michael J Müller, Matthias Fuchs, Vera Gumpp, Annette Schmitt-Graeff, Richard Fischer, Melanie Frank, Oliver Opitz, Jens Hasskarl

Jan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany
Michael J Müller, Jens Hasskarl, Department of Hematology and Oncology, University Medical Center Freiburg, 79104 Freiburg, Germany
Michael J Müller, Matthias Fuchs, Vera Gumpp, Oliver Opitz, Comprehensive Cancer Center Freiburg, Tumorzentrum Ludwig Heilmeyer, University Medical Center Freiburg, 79104 Freiburg, Germany
Annette Schmitt-Graeff, Institute of Pathology, University Medical Center Freiburg, 79104 Freiburg, Germany
Richard Fischer, Onkologie Dreiländereck, 79539 Lörrach, Germany
Melanie Frank, iOMEDICO AG Freiburg, 79108 Freiburg im Breisgau, Germany

Author contributions: Hasskarl J, Müller MJ and Harder J designed the research; Hasskarl J, Müller MJ, Fuchs M, Harder J and Schmitt-Graeff A performed the research; Gumpp V, Frank M, Opitz O, Hasskarl J, Müller MJ and Harder J analyzed the data; Hasskarl J, Müller MJ, Fischer R, Opitz O and Harder J wrote the manuscript; Harder J and Müller MJ contributed equally to this work.

Correspondence to: Jan Harder, MD, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, Virchowstraße 10, 78221 Singen, Germany. jan.harder@hbh-kliniken.de
Telephone: +49-7731-892700 Fax: +49-7731-892705
Received: May 2, 2013 Revised: September 15, 2013 Accepted: September 29, 2013 Published online: December 28, 2013

Abstract

AIM: To investigate the expression and clinical relevance of inhibitor of differentiation (ID) proteins in biliary tract cancer.

METHODS: ID protein expression was analyzed in 129 samples from patients with advanced biliary tract cancer (BTC) (45 extrahepatic, 50 intrahepatic, and 34 gallbladder cancers), compared to normal controls and correlated with clinical and pathological parameters.

RESULTS: ID1-3 proteins are frequently overexpressed in all BTC subtypes analyzed. No correlation between increased ID protein expression and tumor grading, tumor subtype or treatment response was detected. Survival was influenced primarily tumor localization (extrahepatic vs intrahepatic and gall bladder cancer, OS 1.5 years vs 0.9 years vs 0.7 years, P = 0.002), by stage at diagnosis (OS 2.7 years in stage I vs 0.6 years in stage IV, P < 0.001), resection status and response to systemic chemotherapy. In a multivariate model, ID protein expression did not correlate with clinical prognosis. Nevertheless, there was a trend of shorter OS in patients with loss of cytoplasmic ID4 protein expression (P = 0.076).

CONCLUSION: ID protein expression is frequently deregulated in BTC but does not influence clinical prognosis. Their usefulness as prognostic biomarkers in BTC is very limited.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Biliary tract cancer; Cholangiocarcinoma; Inhibitor of differentiation; Prognostic factors

Core tip: Cholangiocarcinoma present as heterogeneous tumors with generally poor prognosis. Molecular changes that drive tumor development are poorly understood, and no valid prognostic markers other than stage and performance status have been identified. Here we analyzed the protein expression of the four inhibitor of differentiation (ID)-proteins by immunohistochemistry in 129 patients with advanced biliary tract cancer, which showed a deregulated ID protein expression in cancer cells and this protein expression partly correlated with the overall survival of patients. Therefore the ID-proteins maybe useful prognostic markers.
INTRODUCTION

Cholangiocarcinomas/biliary tract cancers (BTC) form a heterogeneous group of tumors consisting of intrahepatic mass forming type biliary tract cancer (IHC), perihilar Klatskin tumors, extrahepatic BTC (EHC), and gallbladder cancer (GBC)[1,2]. More than 50% of tumors are diagnosed at an advanced stage. Prognosis is dismal with a mean overall survival of 7 to 8 mo. Although expression of oncogenes such as K-ras, c-myc, c-neu, c-met, and bcl-2, or inactivation of tumor suppressor genes like p53 in BTC has been described[3,4], the pathogenesis and molecular biology of this tumor entity is poorly understood. A recent analysis of liver-fluke associated biliary tract cancer on eight tumors and matched normal tissue identified mutations in three signaling pathways, namely histone modification, G protein activation, and genomic instability[5]. Validation of 15 of the identified 187 mutated genes in another 46 cases of BTC confirmed the role of p53, K-ras, and SMAD-4, and identified additional mutations in genes not prior associated to BTC[6].

The inhibitor of DNA-binding (ID) proteins, ID1-4, are members of the larger family of basic Helix-Loop-Helix (bHLH) transcription factors, which share a basic domain necessary for DNA-binding[7]. ID proteins lack this DNA-binding domain and inhibit transcription of target genes such as p21WAF1/CIP1, p16INK4a, and pRb by forming DNA-binding incompetent heterodimers with other bHLH factors. Various cellular processes are regulated by individual ID-proteins: Inhibition of cellular differentiation by interference with differentiation-specific bHLH and non-bHLH transcription factors[8], extension of cellular life span[9,10], regulation of angiogenesis[11], and maintenance of embryonic and adult stem cells[12], and chromosomal instability[13,14]. ID expression is deregulated in many tumors including pancreatic cancer[15] a malignancy somehow related to BTC. In some cases ID-expression is associated with poor clinical prognosis[16]. Until now, no data on ID protein expression in biliary tract cancer is available, although methylation of the ID4 promoter has been reported in some instances[17].

To investigate the role of ID proteins in BTC we analyzed the expression of ID proteins 1-4 in tumor specimen from 129 patients with advanced BTC and in 9 normal controls by immunohistochemistry (IHC).

MATERIALS AND METHODS

Archival tumor samples and controls

The institutional database of the University Medical Center Freiburg, Germany, was retrospectively searched for patients presenting with advanced BTC between 1996 and 2007. Archival hematoxylin and eosin (HE) stained slides from routinely processed paraffin-embedded samples collected at time of the initial diagnosis were reviewed to verify the diagnosis and to choose representative blocks for further evaluation. Control tissue samples included normal liver with normal biliary structures obtained from 9 male autopsy cases that had died without any evidence of liver or cardiac disease. Samples from tonsils, lymph nodes and colon mucosa were used as positive controls. The study was in accordance with the ethical standards set by the institutional ethics committee and was conducted according to the declaration of Helsinki.

Staging

Staging was performed according to UICC/AJCC recommendations.

Immunohistochemistry

Fresh serial sections were cut at 2 μm from the original diagnostic paraffin-embedded tissue blocks, mounted on Superfrost Plus slides, dried overnight at 37 °C, deparaffinized in xylene and rehydrated through a graded series of alcohol solutions. Antigen retrieval was performed in Target Retrieval Solution (ID1, ID2, ID4: pH6; ID3: pH8; Dako, Glostrup, Denmark) at 95 °C for 60 min. Immunostaining was performed using a semi-automatically autostainer (Dako). The sections were incubated for 60 min at room temperature with primary polyclonal rabbit antibodies against relevant ID proteins (Santa Cruz Biotechnology, Santa Cruz, CA, United States) at different dilutions (ID1, C-20: sc-488 at 1:1000; ID3, C-20: sc-490 at 1:100; ID4: H-70: sc-13047 at 1:100). After washing with PBS, the samples were incubated with biotinylated goat anti-polyvalent antibodies for 15 min and subsequently by streptavidin-alkaline phosphatase for 15 min according to the labeled streptavidin-biotin (LSAB) method. The ID protein binding sections were visualized by K 5005, Fast-Red-Chromogen (Dako) detection for 10 min. Nuclei were counterstained with Mayer’s hemalaun solution. Vascular smooth muscle cells served as internal positive controls for the ID proteins. As a negative control, the primary antibody was omitted, with all other experimental conditions kept constant. The staining specificity was further confirmed by blocking the antibody binding to the antigen with the corresponding blocking peptides for ID1, ID2 and ID3 (Santa Cruz). No blocking peptide was commercially available for ID4.

Scoring of the immunohistochemical staining

Two blinded observers independently evaluated all cases. For cases with discordant scoring results, a consensus was obtained by reevaluating the slides. When the tumor samples showed a heterogeneous staining pattern, the “hot spots” showing the highest staining intensity were selected for further quantification. Cytoplasmic and nuclear immunolabeling were evaluated. Cytoplasmic ex-
pression was scored according to the staining intensity (0, negative; 1, low; 2, moderate to 3, strong). Nuclear staining was scored according to the percentage of positive nuclei. At least 100 nuclei were assessed in the hot spots at high magnification (× 400). The percentage of positive cells was rated as follows: 0: 0%-10%, 1: 11%-50%, 2: 51%-80%, and 3: 81%-100% of tumor cell nuclei positive.

**Statistical analysis**

Statistical analysis was performed using SPSS 15.0 statistical software (SPSS, Inc, Chicago, Illinois). Both the analysis of the association of ID1-4 expression levels in BTC with the overall survival (OS) and the correlation of tumor subtypes with OS were performed by the chi-square test with \( P < 0.05 \) considered as statistically significant. Overall survival was defined as the interval from date of diagnosis (histopathology) until death from any cause. Additionally to the analysis with the whole study cohort \( (n = 129) \), the patients were divided into the two following subgroups: Patients treated by chemotherapy \( (n = 64) \) and patients not treated by chemotherapy \( (n = 56) \). Survival estimates were calculated using the Kaplan-Meier method. To test for independent relevance of the candidate prognostic factors a multivariate Cox proportional hazards regression model was fit for each of the ID-proteins. All baseline characteristics plus cytoplasmic and nuclear expression of the respective ID-protein were included in the model. Tumor stage and grading were dichotomized \((1/2 vs 3/4)\).

**RESULTS**

We identified 129 cases of advanced BTC (unresectable at time of presentation in our institution) that had been treated at our institution between June 1998 and June 2005. Thirty-five percent \( (n = 45) \) were of extrahepatic origin (EHC), 39% \( (n = 50) \) were of intrahepatic origin (IHC), and 26% \( (n = 34) \) were gallbladder cancers (GBC). Median age at diagnosis was 62.2 years \( (\text{range 32-84 years}) \) with even gender distribution \((48\% \text{ female, } 52\% \text{ male})\). The majority of patients had developed metastatic disease; most tumors were G2 tumors \((63\%)\). Patients were treated with best supportive care \( (n = 56) \) and various chemotherapeutic regimens \( (n = 64) \). Nine patients had become secondary resectable \((R0)\). Chemotherapy regimens were 5-FU or gemcitabine based, often in combination with cisplatin or oxalaplatin. Response to treatment was monitored by CT, MRI or ultrasound according to the standard WHO criteria \((\text{WHO}, 1979)\). Eleven patients \( (17\%) \) showed a partial remission, \( 27\% \text{ (42\%) had stable disease, and 26 patients (41\%) had progressive disease despite chemotherapy. Follow-up data were available from all 129 patients with a median follow-up of 16.5 mo. The median overall survival for all patients was 18.3 mo (Table 1).

To identify prognostic subgroups standard clinical prognostic variables were correlated with clinical outcome. As expected from clinical experience, site of the primary tumor clearly influenced prognosis. Patients with EHC had a significantly longer OS compared to patients with IHC and GBC \((\text{Median OS 1.5 years vs 0.6 years, } P = 0.001)\) (Figure 1). Overall survival from time of diagnosis was also influenced by stage at diagnosis \((\text{Stage I: 2.7 years vs stage II: 2.0 years vs stage III: 0.9 years vs stage IV: 0.6 years, } P < 0.001)\). Resection status also influenced survival, which was longer in patients with completely resected \((R0)\) tumors compared to incompletely resected \((R1/R2)\) and not surgically treated tumors \((\text{OS 2.0 years vs 1.3 years vs 0.6 years, } P < 0.001)\). Likewise, OS was better in patients whose tumors responded to chemotherapy \((\text{PR 2.0 years vs SD 1.3 years vs PD 0.6 years, } P = 0.003)\). To exclude an influence of curative resection \( (n = 9) \) on the results, a sensitivity analysis excluding these cases was performed that confirmed the results \( (P = 0.004)\). Because of the small sample size no additional subgroup analyses were performed.

---

**Table 1 Patient characteristics, survival and best response to treatment \( n (\%) \)**

| Age (yr) | Median (62.2) | Range (32-84) |
|---------|---------------|---------------|
| Sex     | Male 67 (51.9) | Female 62 (48.1) |
| BTC subtype | EHC 45 (34.9) | IHC 50 (38.6) | GBC 34 (26.4) | Total 129 |
| Stage   | I 10 (7.8) | II 20 (15.5) | III 40 (31.0) | IV 65 (50.4) |
| Grade   | G1 7 (5.4) | G2 81 (62.8) | G3 41 (31.8) |
| Treatment | BSC 56 (43.4) | Cx 64 (49.6) | Sx 9 (7.0) | Total 129 |
| Response to Cx | PR 11 (17.2) | SD 27 (42.2) | PD 26 (40.6) |
| OS      | BSC 15.1 | Cx 17.7 | Sx 41.8 | All 18.3 |

**Figure 1** Survival of patients with biliary tract cancer by primary tumor localization. Kaplan-Meier estimates of overall survival in patients with extrahepatic biliary tract cancer (BTC) \( (n = 45) \), intrahepatic BTC \( (n = 50) \) and gall bladder cancer \( (n = 34) \).
of ID1, ID2, and ID3 was undetectable or low in normal tissue, similarly high cytoplasmic and nuclear ID1 expression was detected in 63.6%, and 61.3% of BTC cases (Figure 3). Likewise, high ID2 expression was detected, which was mainly cytoplasmic (77.5% cytoplasmic vs 4.7% nuclear). ID3 was highly expressed in the cytoplasm (40.3%) and even more pronounced in the nucleus (68.3%). In contrast, all normal controls analyzed expressed high levels of nuclear ID4, but only low levels of cytoplasmic ID4. In BTC, this predominant nuclear ID4 staining was reduced to 77.8%.

To investigate the clinical relevance of the above findings, ID protein expression was correlated with overall survival (OS), tumor grade, tumor stage, prior...
Table 2  Inhibitor of differentiation protein expression and tumor characteristics ($\alpha$ (%))

| Total (n) | IHC | EHC | GBC | Stage I | Stage II | Stage III | Stage IV | G1 | G2 | G3 |
|-----------|-----|-----|-----|--------|---------|-----------|---------|----|----|----|
| ID1 neg   | 17  | 6 (5)| 6 (5)| 5 (4)  | 1 (1)   | 2 (2)     | 4 (3)   | 10 (8)| 1 (1)| 9 (7)| 7 (5)|
| ID1 pos   | 112 | 44 (34)| 39 (30)| 29 (22)| 9 (7)  | 18 (14)| 30 (23)| 55 (43)| 6 (5)| 72 (56)| 34 (26)|
| ID2 neg   | 29  | 13 (10)| 9 (7) | 7 (5)  | 1 (1)   | 3 (2)     | 9 (7) | 16 (12)| 2 (2)| 19 (15)| 8 (6) |
| ID2 pos   | 100 | 37 (29)| 36 (28)| 27 (21)| 9 (7)  | 17 (13)| 25 (19)| 49 (38)| 5 (4)| 62 (48)| 33 (26)|
| ID3 neg   | 25  | 9 (7)  | 9 (7) | 7 (5)  | 1 (1)   | 7 (5)     | 3 (2) | 14 (11)| 2 (2)| 15 (12)| 8 (6) |
| ID3 pos   | 104 | 41 (32)| 36 (28)| 27 (21)| 9 (7)  | 13 (10)| 31 (24)| 51 (40)| 5 (4)| 66 (51)| 33 (36)|
| ID4 neg   | 26  | 11 (9) | 9 (7) | 6 (5)  | 2 (2)   | 7 (6)     | 9 (7) | 8 (7) | 1 (1)| 15 (12)| 10 (8) |
| ID4 pos   | 96  | 35 (29)| 35 (29)| 26 (21)| 8 (7)  | 13 (11)| 23 (19)| 52 (43)| 6 (5)| 61 (50)| 29 (24)|

EHC: Extrahepatic biliary tract cancer (BTC); IHC: Intrahepatic BTC; GBC: Gallbladder cancer; G: Grade.

Figure 3  Proportion of inhibitor of differentiation protein expression in biliary tract cancer and normal intrahepatic bile ducts. A: Percentage of biliary tract cancer (BTC) with high expression of the respective inhibitor of differentiation (ID) protein in BTC (black bars) and normal intrahepatic bile ducts (control; grey bars); B: Summary of ID protein expression. Overall ID protein expression ID protein expression was scored in low (0+1) and high (2+3) and assessed for nuclear and cytoplasmic (cyto) staining pattern. Cytoplasmic staining intensity was scored 0 (negative) to 3 (strong), nuclear expression was assessed for nuclear positive nuclei (0: 0%-10%; 1: 11%-50%; 2: 51%-80%; and 3: 81%-100%). For ID4, only 122 samples could be analyzed. C: Cytoplasmic expression; N: Nuclear expression.

chemistry, and response to chemotherapy. Correlation of ID expression with OS was calculated for the whole study cohort ($n = 129$; $n = 122$ for ID4) and for the subgroups of patients treated with chemotherapy ($n = 64$) and patients not treated by chemotherapy ($n = 56$). While neither cytoplasmic nor nuclear ID1 expression was correlated with OS, a clear trend for shorter OS was observed for nuclear negative ($n = 27$) vs nuclear positive ($n = 102$) cases (0.9 years vs 1.2 years, $P = 0.058$) (Figure 4A). Further subgroup analyses identified a strong correlation of ID1 expression and overall survival in chemotherapy naïve patients ($n = 56$). Here, patients without nuclear ($n = 10$) ID1 expression had an OS of 2.1 years compared to 0.5 years in patients with nuclear ($n = 46$) ID1 expression ($P = 0.001$) (Figure 4B). ID2 did not have a prognostic value for the overall study population ($P = 0.79$ for cytoplasmic expression, $P = 0.28$ for nuclear expression). Nevertheless, in the subgroup of patients who had received chemotherapy ($n = 64$) patients without nuclear ID2 expression ($n = 51$) had a significantly better prognosis than patients with nuclear ID2 expression ($n = 13$), with OS of 1.3 years and 0.5 years, respectively ($P = 0.001$) (Figure 4C). As for ID1 and ID2, ID3 expression in the overall study population did not correlate with OS ($P = 0.28$ for cytoplasmic, and $P = 0.44$ for nuclear ID3 expression). The subgroup of patients who had received chemotherapy ($n = 64$) patients without cytoplasmatic ID3 expression ($n = 36$) had a slightly better prognosis than patients with cytoplasmatic ID3 expression ($n = 28$), with OS of 1.0 years and 1.1 years, respectively ($P = 0.037$) (Figure 4D). Using the same subgroup analyses as for the other IDs, no relevant subgroup was identified. Quite strikingly, while nuclear ID4 expression did not correlate with OS ($P = 0.27$), cytoplasmic ID4 expression seemed to correlate with prognosis (Figure 4E). Overall survival in patients with cytoplasmatic ID4 expression ($n = 60$) was 1.2 years compared with 0.6 years in patients without cytoplasmatic ID4 expression ($n = 62$, $P = 0.001$) in univariate analysis. This was reproduced in the subgroup of patients who had not received prior chemotherapy ($n = 56$). Here, OS was 1.1 years vs 0.5 years in patients with cytoplasmatic ($n = 23$) vs no cytoplasmic ($n = 33$) ID4 expression ($P = 0.025$) (Figure 4F). Analyses of ID1-4 expression and other clinical-pathological variables failed to show any significant correlation (data not shown). Specifically, ID expression levels were similar in EHC, IHC, and GBC.

To test the relevance of the above findings a multivariate Cox proportional hazards regression model was used. Multivariate testing confirmed the importance of tumor localization, surgical treatment, and response to chemotherapy as factors influencing survival (Table 3). Patients with extrahepatic BTC have the best prognosis (HR = 0.32, 95%CI: 0.18-0.6, $P < 0.0005$), as have patients who had been treated surgically (HR = 0.3, 95%CI: 0.17-0.55, $P < 0.0001$). Patients responding to chemotherapy with
a partial remission (PR) or disease stabilization (SD) likewise seem to have a better clinical prognosis (HR = 0.43, 95%CI: 0.20-0.91, P = 0.267; and HR 0.4, 95%CI: 0.22-0.71, P = 0.002, respectively). The effects of the ID proteins observed in univariate testing did not reach statistical significance in this multivariate model. Only tumors with loss of cytoplasmatic ID4 expression showed a trend for shorter survival (HR = 0.68, 95%CI: 0.45-1.04, P = 0.0736).

**DISCUSSION**

Our analysis of 129 cases of biliary tract cancer confirmed the importance of primary tumor localization, tumor stage, resection status and response to chemotherapy. We believe that our findings are valid, as also patients who
had not been curatively resected had a significantly longer OS (P = 0.004). Hence, information of primary BTC localization should be prospectively evaluated and used for stratification in clinical trials in advanced BTC to verify its prognostic relevance. It is hard to speculate on factors influencing this different prognosis. One report could hint to a role of the multidrug resistance proteins (MRP) showing lower levels of MRP3 in EHC compared to gallbladder carcinomas[19]. Alternatively, differential gene expression as of matrix metalloproteinases and growth factors might contribute to the different biological behavior of EHC[18,20].

While data on ID protein expression in BTC was scarce, more comprehensive data is available for ID expression in hepatocellular carcinoma (HCC). In HCC, ID1 is frequently expressed and higher ID1 expression was reported to correlate with decreased p16INK4A expression[21]. ID protein expression decreased with loss of differentiation, suggesting a role of ID proteins in early carcinogenesis[22]. Contrasting these results are data that imply a role of ID1 in progression, metastasis, and tumor vessel formation[19,21-23]. Immunohistochemical analysis of liver tissue from 112 patients with liver cirrhosis showed elevated ID1 expression in 38% (n = 42) of patients. These patients were at higher risk of developing HCC[23]. In an analysis of 80 matched pair biopsies of HCC and normal liver, and cirrhotic and chronic hepatitis samples no ID1-protein expression was observed in normal liver, whereas moderate to strong ID1 expression was detected in 50% of HCCs. In 60 matched pairs of primary tumor and metastasis, expression in the metastases was higher (90%) than in the primary tumors (42%), correlating with increased VEGF expression[24]. In a nude mouse model ID1 induced VEGF by stabilizing HIF alpha, and antisense-inhibition of ID1 resulted in decreased tumor growth due to decreased VEGF expression and decreased tumor vascularization[22].

Analysis of ID protein expression in our cohort of cholangiocarcinomas showed expression of all four ID proteins. ID4 was the only ID protein expressed in normal bile ducts. Neither overall ID protein expression levels nor subcellular localization correlated used and for estratification in clinical trials in advanced BTC to verify its prognostic relevance. While loss of ID4 protein expression was frequently detected and patients with ID4 negative tumors had a trend for shorter OS this needs to be confirmed in a larger sample. The role of ID4 on tumor development is still not fully understood. Recent studies revealed that the ID4 gene can be silenced through promoter hypermethylation in various tumors, including BTC[32,33], suggesting a tumor suppressive role. On the other hand ID4 was identified as an upstream regulator of BRCA1 in breast and ovarian cancer[34]. Also supporting an oncogenic role of ID4 are reports describing activating translocations of ID4 in some patients with bladder cancer and a subset of patients with acute lymphoblastic leukemia[35,36]. Our data suggest a tumor suppressive role of ID4 in BTC, as patients without or with low cytoplasmic levels of ID4 had shorter overall survival. While hypothesis generating, this must be confirmed and validated in a larger patient population. In summary, we have shown that ID protein expression is deregulated in biliary tract cancer but that their use as prognostic biomarkers is very limited.

Table 3  Multivariate analysis of clinical characteristics and inhibitor of differentiation protein expression

| ID1          | HR  | 95%CI   | P value | ID2          | HR  | 95%CI   | P value | ID3          | HR  | 95%CI   | P value | ID4          | HR  | 95%CI   | P value |
|--------------|-----|---------|---------|--------------|-----|---------|---------|--------------|-----|---------|---------|--------------|-----|---------|---------|
| Gender (male)| 1.17| 0.76-1.80| 0.4717  | 1.07         | 0.71-1.64| 0.763   | 1.03    | 0.68-1.56| 0.8877       | 1.29| 0.82-2.02| 0.267   |
| IHC          | 0.57| 0.33-0.97| 0.0399  | 0.66         | 0.39-1.11| 0.1193  | 0.72    | 0.42-1.23| 0.2332       | 0.75| 0.44-1.28| 0.295   |
| EHC          | 0.32| 0.18-0.60| 0.0003  | 0.36         | 0.20-0.64| 0.0005  | 0.36    | 0.20-0.63| 0.0003       | 0.32| 0.18-0.57| 0.0001  |
| Stage II-V   | 1.51| 0.80-2.83| 0.2037  | 1.5         | 0.80-2.80| 0.2051  | 1.72    | 0.91-3.25| 0.0928       | 1.24| 0.65-2.35| 0.5129  |
| Grade 3      | 1.57| 0.99-2.50| 0.0532  | 1.58         | 1.01-2.47| 0.0471  | 1.43    | 0.90-2.27| 0.1326       | 1.53| 0.96-2.45| 0.0732  |
| Surgery      | 0.3 | 0.17-0.55| < 0.0001| 0.35         | 0.20-0.61| 0.0003  | 0.33    | 0.18-0.61| 0.0004       | 0.31| 0.17-0.55| < 0.0001|
| Age          | 0.99| 0.97-1.01|         | 0.99         | 0.97-1.01| 0.3835  | 0.99    | 0.97-1.01| 0.3188       | 0.99| 0.97-1.02| 0.6452  |
| Response to Cx | 0.81| 0.44-1.47| 0.4836  | 0.83         | 0.45-1.53| 0.5442  | 0.65    | 0.35-1.20| 0.1669       | 0.7  | 0.37-1.31| 0.261   |
| Response to Cx SD | 0.4 | 0.22-0.71| 0.002   | 0.4          | 0.22-0.72| 0.0021  | 0.33    | 0.19-0.60| 0.0002       | 0.37| 0.20-0.67| 0.0012  |
| Response to Cx PR | 0.43| 0.20-0.91| 0.0267  | 0.48         | 0.23-0.98| 0.0426  | 0.46    | 0.22-0.94| 0.0329       | 0.5  | 0.25-1.01| 0.0531  |
| Nuclear low  | 0.93| 0.46-1.88| 0.8447  | 1.41         | 0.80-2.50| 0.2333  | 1.32    | 0.62-2.79| 0.4721       | 0.94| 0.38-2.33| 0.8979  |
| Nuclear high | 1.2 | 0.65-2.20| 0.5563  | 1.51         | 0.19-11.84| 0.696   | 0.97    | 0.47-2.00| 0.9275       | 0.63| 0.27-1.47| 0.813   |
| Cytoplasmic low | 0.81| 0.34-1.91| 0.6276  | 0.39         | 0.07-4.80| 0.6195  | 1.0     | 0.60-1.68| 0.9948       | 0.68| 0.45-1.04| 0.0736  |
| Cytoplasmic high | 0.81| 0.34-1.90| 0.6261  | 0.64         | 0.08-5.04| 0.6703  | 0.71    | 0.33-1.54| 0.3866       | 0.31| 0.03-2.85| 0.3028  |

n = 129, number of events = 119, r² = 0.386 for ID1-3, r² = 0.392 for ID4; EHC: Extrahepatic biliary tract cancer (BTC); IHC: Intrahepatic BTC; Cx: Chemotherapy; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ID: Inhibitor of differentiation.

| n = 129, number of events = 119, r² = 0.386 for ID1-3, r² = 0.392 for ID4; EHC: Extrahepatic biliary tract cancer (BTC); IHC: Intrahepatic BTC; Cx: Chemotherapy; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ID: Inhibitor of differentiation.|

**ACKNOWLEDGMENTS**

The authors thank Blum H, and Mertelsmann R for continuous support.

**COMMENTS**

**Background**

Cholangiocarcinoma present as heterogeneous tumors with generally poor prognosis. Molecular changes that drive tumor development are poorly understood, and no valid prognostic markers other than stage and performance status have been identified.

**Innovations and breakthroughs**

To investigate the role of inhibitor of differentiation (ID) proteins in biliary tract cancer (BTC) we analyzed the expression of ID proteins 1-4 in tumor specimens
from 129 patients with advanced BTC and in 9 normal controls by immunohistochemistry.

**Applications**

Authors have shown that ID protein expression is deregulated in biliary tract cancer but that their use as prognostic biomarkers is very limited.

**Peer review**

The authors described the expressions of ID-1 proteins in specimens of cholangiocarcinoma and compared to the normal control. An interesting paper looking for new histological parameters in cholangiocarcinoma.

**REFERENCES**

1. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. *J Hepatol* 2006; 45: 856-867 [PMID: 17030071 DOI: 10.1016/j.jhep.2006.09.001]

2. de Groen PC, Gores GJ, LaRusso NF, Gundersen LL, Nagorney DM. Biliary tract cancers. *N Engl J Med* 1999; 341: 1368-1378 [PMID: 10536130]

3. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graef A, Optiz OG. EGF and HER2 expression in advanced biliary tract cancer. *World J Gastroenterol* 2009; 15: 4511-4517 [PMID: 19776969]

4. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinoma. *Semin Liver Dis* 2011; 31: 173-187 [PMID: 21538283 DOI: 10.1055/s-0031-1276646]

5. Ong CK, Subinerving C, Pairojuclk C, Wongkhram S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, Myint SS, Rajasegaran V, Heng HL, Can A, Zang ZJ, Wu Y, Wu J, Lee MH, Huang D, Ong P, Chan-on W, Cao Y, Qian CN, Lim KH, Ooi A, Dykema K, Furge K, Kungkongviriyapan V, Sripa B, Wongkhram C, Yongvanit P, Futeaal PA, Bhudhisawasd V, Rozen S, Tan P, Teh BT. Exome sequencing of liver fluke-associated cholangiocarcinoma. *Nat Genet* 2012; 44: 690-693 [PMID: 22561520 DOI: 10.1038/ng.2273]

6. Perk J, Ivavoren A, Benezra R. Id family of helix-loop-helix proteins in cancer. *Nat Rev Cancer* 2005; 5: 603-614 [PMID: 16034366 DOI: 10.1038/nrc1367]

7. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. *Cell* 1990; 61: 49-59 [PMID: 2156629]

8. Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA, Muegter M. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. *Proc Natl Acad Sci USA* 1999; 96: 9637-9641 [PMID: 10449746]

9. Tang J, Gordon GM, Nickoloff BJ, Foreman KE. The helix-loop-helix protein id-1 delays onset of replicative senescence in human endothelial cells. *Lab Invest* 2002; 82: 1073-1079 [PMID: 12177246]

10. Nickoloff BJ, Chaturvedi V, Bacon P, Qin JZ, Denning MF, Diaz MO. Id-1 delays senescence but does not immortalize keratinocytes. *J Biol Chem* 2000; 275: 27501-27504 [PMID: 10980559 DOI: 10.1074/jbc.C00031200]

11. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Cryst RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nat Med* 2001; 7: 1194-1201 [PMID: 11689883 DOI: 10.1038/nm1101-1194]

12. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. *Cell* 2003; 115: 281-292 [PMID: 14635566]

13. Hasskarl J, Duensing S, Manuel E, Muegter K. The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers. *Oncogene* 2004; 23: 1903-1938 [PMID: 14755252 DOI: 10.1080/sj.1207310]

14. Wang X, Di K, Zhang X, Han HY, Wong YC, Leung SC, Ling MT. Id-1 promotes chromosomal instability through modification of APC/C activity during mitosis in response to microtubule disruption. *Oncogene* 2008; 27: 4456-4466 [PMID: 18372912 DOI: 10.1038/onc.2008.87]

15. Hasskarl J, Muegter K. Id proteins—tumor markers or onco genes? *Cancer Biol Ther* 2002; 1: 91-96 [PMID: 12170780]

16. Uhm KO, Lee ES, Lee YM, Kim HS, Park YN, Park SH. Alterant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. *Oncol Res* 2008; 17: 151-157 [PMID: 18773859]

17. Rau S, Autschbach F, Riedel HD, Konig J, Kaluszkiz H, Steihl A, Riemann JF, Rost D. Expression of the multidrug resistance proteins MR22 and MRP3 in human cholangiocellular carcinomas. *Eur J Clin Invest* 2008; 38: 134-142 [PMID: 18226047 DOI: 10.1111/j.1365-2627.2007.01916.x]

18. Kirimiöiu H, Türkmen I, Başsullü N, Dirican A, Karadağ N, Kirimiöiu V. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis. *Turk J Gastroenterol* 2009; 20: 41-47 [PMID: 19330734]
Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sibitzky F, Plass C, Byrd JC. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011; 117: 862-871 [PMID: 21098398 DOI: 10.1182/blood-2010-05-284638]

Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 2005; 37: 265-274 [PMID: 15723065 DOI: 10.1038/ng1521]

Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welch P, Welch PJ, Welte K, King MC, Barber JR, Wong-Staal F. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA 2001; 98: 130-135 [PMID: 11136250 DOI: 10.1073/pnas.98.1.130]

Bellido M, Aventin A, Lasas A, Estivill C, Carnicer Mj, Pons C, Matias-Guiu X, Bordes R, Baiget M, Sierra J, Nonmededau JF. Id4 is deregulated by a t(6; 14)(p22; q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia. Haematologica 2003; 88: 994-1001 [PMID: 12969807]

Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol Cancer 2005; 4: 16 [PMID: 15876350 DOI: 10.1186/1476-4598-4-16]

Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Loraine Karran E, Nagel I, Harder L, Claviez A, Gek S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJ, Harrison CJ. t(6; 14)(p22; q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008; 111: 387-391 [PMID: 17940204 DOI: 10.1182/blood-2007-07-092015]
Published by Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China
Fax: +852-65557188
Telephone: +852-31779906
E-mail: bpgoffice@wjgnet.com
http://www.wjgnet.com